---
title: "Beyond the Scale: What Else Glucagon-like Peptide-1 Receptor Agonists Can Do"
id: "endocrine-news-34-beyond-the-scale-what-else-glucagon-like-peptide-1-receptor-agonists-can-do"
canonical_url: "https://medichelpline.com/clinical-feed/endocrine-news-34-beyond-the-scale-what-else-glucagon-like-peptide-1-receptor-agonists-can-do"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "Endocrine News"
source_url: "https://endocrinenews.endocrine.org/beyond-the-scale-what-else-glucagon-like-peptide-1-receptor-agonists-can-do/"
published_at: "2026-02-13T16:23:57.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Beyond the Scale: What Else Glucagon-like Peptide-1 Receptor Agonists Can Do
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/endocrine-news-34-beyond-the-scale-what-else-glucagon-like-peptide-1-receptor-agonists-can-do
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** Endocrine News
- **Source URL:** [Original Journal Publication](https://endocrinenews.endocrine.org/beyond-the-scale-what-else-glucagon-like-peptide-1-receptor-agonists-can-do/)
- **Published At:** 2026-02-13T16:23:57.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
In the United States, American Heart Month is observed in February to raise awareness about cardiovascular disease, the leading cause of death worldwide. To a similar end, Endocrine News focuses on a few recent journal studies that take a closer look at the impacts of incretin-based therapies in the setting of obesity and impaired cardiovascular health, as well as how they affect the liver, quality of life, insulin resistance, and much more. February is heart month at Endocrine News , making it an opportune time to examine four recent studies that explore various aspects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and related incretin-based therapies, given obesity’s profound impact on cardiovascular health. Recent advances in obesity pharmacotherapy have shown unprecedented efficacy in weight reduction and cardiometabolic improvement. GLP-1RAs (and their offshoots that add agonists of other key metabolic regulation substances) have shown particular promise in patients with obesity-related cardiovascular and metabolic complications, offering synergistic benefits that extend beyond weight loss.
## Clinical Analysis & Structured Key Points
Endocrine News published a clinical update in Research Highlights on 13 Feb 2026. The item focuses on Beyond the Scale: What Else Glucagon-like Peptide-1 Receptor Agonists Can Do. Review the original article for the full source wording and details.
## Related Clinical Research

- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)
- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)
- [SGLT2 inhibitors vs GLP-1 RAs and osteoarthritis risk in type 2 diabetes: a multi-institutional co](https://medichelpline.com/clinical-feed/plos-one-16-comparative-effects-of-sglt2-inhibitors-and-glp-1-receptor-agonists-on.md)
- [No Patient Left Behind: Expanding Semaglutide’s Reach](https://medichelpline.com/clinical-feed/endocrine-news-21-no-patient-left-behind-expanding-semaglutide-s-reach.md)
- [Orforglipron Added to Titrated Insulin Glargine Improves Glycemic Control and Weight in Type 2 Dia](https://medichelpline.com/clinical-feed/pubmed-42251769.md) (DOI: 10.1001/jama.2026.9512)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.